EP1208112A1 - Isogenes cibles pour medicament: polymorphismes dans le gene recepteur 1a de la 5-hydroxytryptamine - Google Patents

Isogenes cibles pour medicament: polymorphismes dans le gene recepteur 1a de la 5-hydroxytryptamine

Info

Publication number
EP1208112A1
EP1208112A1 EP00962018A EP00962018A EP1208112A1 EP 1208112 A1 EP1208112 A1 EP 1208112A1 EP 00962018 A EP00962018 A EP 00962018A EP 00962018 A EP00962018 A EP 00962018A EP 1208112 A1 EP1208112 A1 EP 1208112A1
Authority
EP
European Patent Office
Prior art keywords
htria
gene
haplotype
polymoφhic
nucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00962018A
Other languages
German (de)
English (en)
Inventor
R. Rex Denton
Stefanie E. Kliem
Krishnan Nandabalan
Joel Claiborne Stephens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cogenics Inc
Original Assignee
Genaissance Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genaissance Pharmaceuticals Inc filed Critical Genaissance Pharmaceuticals Inc
Publication of EP1208112A1 publication Critical patent/EP1208112A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This invention relates to variation in genes that encode pharmaceutically important proteins.
  • this invention provides genetic variants of the human 5-hydroxytryptamine receptor 1 A gene (HTRIA) gene and methods for identifying which variant(s) of this gene is/are possessed by an individual.
  • HTRIA human 5-hydroxytryptamine receptor 1 A gene
  • a target protein currently used to screen drugs typically is expressed by a gene cloned from an individual who was arbitrarily selected.
  • the nucleotide sequence of a particular gene may vary tremendously among individuals.
  • Subtle alteration(s) in the primary nucleotide sequence of a gene encoding a target protein may be manifested as significant variation in expression of or in the structure and/or function of the protein.
  • Such alterations may explain the relatively high degree of uncertainty inherent in treatment of individuals with drugs whose design is based upon a single representative example of the target. For example, it is well-established that some classes of drugs frequently have lower efficacy in some individuals than others, which means such individuals and their physicians must weigh the possible benefit of a larger dosage against a greater risk of side effects.
  • haplotype The organization of single nucleotide variations (polymorphisms) in the primary sequence of a gene into one of the limited number of combinations that exist as units of inheritance is termed a haplotype. Each haplotype therefore contains significantly more information than individual unorganized polymorphisms. Haplotypes provide an accurate measurement of the genomic variation in the two chromosomes of an individual.
  • haplotype will provide a superior genetic marker for the phenotype (Clark AG et al. 1998 supra; Ulbrecht M et al. 2000, supra; Ruaiio G & Stephens JC Gen EngNews 19 (21), December 1999).
  • the 5- hydroxytryptamine receptor 1 A gene (HTRIA) gene or its encoded product.
  • the 5- hydroxytryptamine receptor 1A (HTRIA) is one of fourteen known receptors for 5-hydroxytryptamine (5-HT; serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen.
  • Serotonergic pathways are believed to participate in a wide variety of physiological and behavioral processes, including nociception, thermoregulation, cardiovascular function, feeding, aggression, and stress response. Aberrant function in the serotonergic pathway has been implicated in neuropsychiatric diseases such as anxiety, depression, substance abuse, and Tourette's syndrome.
  • 5-HT receptors Serotonin receptors belong to the superfamily of seven-transmembrane domain, G-protein- coupled receptors.
  • the 14 members of the 5-HT receptor family have been classified extensively on the basis of molecular biological, pharmacological, biochemical, and physiological properties. The most thoroughly studied to date is HTRIA.
  • the activity of HTRIA is mediated by G proteins that inhibit the activity of adenylate cyclase.
  • 5HT1 A receptors are expressed in a tissue specific manner, predominantly in the dorsal and median raphe' hippocampus, septal nuclei, amygdala, and certain cortical layers.
  • Presynaptic HTRIA is a classical "autoreceptor" in the raphe' nuclei. Presynaptic serotonergic neurons synthesize the majority of brain serotonin, and activation of HTRIA molecules on these neurons completes a negative feedback loop, inhibiting serotonin synthesis, turnover, and release, thus attenuating system-wide serotonergic signaling. This important regulatory action provides a target for clinical intervention, and has been successfully exploited with HTRIA partial agonists, such as the anxiolytics, buspirone and gepirone.
  • SSRIs selective serotonin reuptake inhibitors
  • SSRIs function by blocking 5-HT binding to the serotonin transporter in the synaptic cleft, thereby elevating the levels of synaptic serotonin.
  • Antagonist blockade of the inhibitory presynaptic HTRIA augments and accelerates the effectiveness of SSRIs.
  • Postsynaptic HTRIA is found primarily in the limbic region (hippocampus, septum) and cerebral cortex, regions where the serotonergic neurons project.
  • the 5-hydroxytryptamine receptor 1A gene gene is located on chromosome 5ql 1.2-ql3 (Kobilka et al., Nature. 1987 329:75-79) and contains 1 exon that encodes a 422 amino acid protein. Although a full genomic sequence has not been published, a reference sequence for the HTRIA gene can be assembled from noncontiguous published sequences. Overlapping sequences for the promoter region and the 5 'end of the exon have been published and are shown in Figure 1 (GenBank Accession No. Zl 1168.1; SEQ ID NO: 1 ), which includes the promoter and 5 'end of the exon, and Figure 2 (GenBank Accession No. Zl 1168.1; SEQ ID NO: 1 ), which includes the promoter and 5 'end of the exon, and Figure 2 (GenBank Accession No. Zl 1168.1; SEQ ID NO: 1 ), which includes the promoter and 5 'end of the exon, and Figure 2 (GenBank Accession No. Zl
  • FIG. 3 A reference sequence for the HTRIA gene is shown in Figure 3 (SEQ ID NO:3; nucleotides 1-784 of GenBank Accession No. Zl 1168.1 and nucleotides 1-1938 of GenBank Accession No. M83181.1). Reference sequences for the coding sequence and protein are shown in Figures 4 (SEQ ID NO:4) and 5 (SEQ ID NO:5), respectively.
  • Significant features of the HTRIA gene include: a lack of typical TATA box elements in the promoter, but instead, extensive runs of GC-rich sequence, particularly the consensus GGGGC/AGGGG sequence, which is indicative of MAZ and Spl transcription factor binding sites (Parks and Shenk, J.
  • HTRIA protein sequence (Fig. 4) include an amino terminus extracellular domain at amino acids (AA) 1-36; seven transmembrane domains at AA 37-62, AA 74-98, AA 110-132, AA153-178, AA 192-217, AA 346-367, and AA 379-403; and a carboxyl terminus cytoplasmic domain at AA 404-422.
  • RFLPs restriction fragment length polymorphisms
  • SNPs single nucleotide polymorphisms
  • a third RFLP for the enzyme Sad is also associated with the HTRIA locus (Khan et al., Nucl. Acids Res. 18:691, 1990), but the polymorphic site is probably found in the flanking regions of the gene, since no Sad sites are found in the reference nucleotide sequence. Additionally, a single nucleotide polymorphism corresponding to a polymorphism of cytosine or thymine at nucleotide position 943 in Figure 2 has been reported in the Human Genie Bi-Allelic Sequences Database (HGBase:SNP000002698; Kawanishi et al., Am. J. Med. Genet. 1998. 81 :434-439) as of July 28, 2000.
  • SNPs that produce variation in the amino acid sequence.
  • the following SNPs in Figure 2 cause amino acid variations in the HTRIA protein: a polymorphism of cytosine or thymine at nucleotide position 438 which results in proline or leucine at AA position 16 (Kawanishi et al., 1998. Am. J. Med. Genet. 81:434-9), a polymorphism of guanine or adenine at nucleotide position 455 which results in glycine or serine at AA position 22 (Nakhai et al., Biochem Biophys. Res. Commun.
  • HTRIA gene Because of the potential for polymorphisms in the HTRIA gene to affect the expression and function of the encoded protein, it would be useful to determine whether additional polymorphisms exist in the HTRIA gene, as well as how such polymorphisms are combined in different copies of the gene. Such information would be useful for studying the biological function of the HTRIA receptor as well as in identifying agonists and/or antagonists targeting this receptor in the treatment of behavioral disorders, such as anxiety and depression.
  • PS polymorphic sites
  • PS5 and 1639 The polymorphisms at these sites are cytosine or thymine at PS1, cytosine or thymine at PS5 and cytosine or guanine at PS6.
  • the inventors have determined the identity of the alternative nucleotides present at these sites, as well as at the previously identified sites at nucleotides 1222 (PS2), 1257 (PS3), 1469 (PS4), 1727 (PS7), 1834 (PS8) and 1993 (PS9), in a human reference population of 79 unrelated individuals self- identified as belonging to one of four major population groups: African descent, Asian, Caucasian and Hispanic/Latino.
  • the invention provides an isolated polynucleotide comprising a nucleotide sequence which is a polymorphic variant of a reference sequence for the HTRIA gene or a fragment thereof.
  • the reference sequence comprises SEQ ID NO:3 and the polymorphic variant comprises at least one polymorphism selected from the group consisting of thymine at PS1, thymine at PS5, and guanine at PS6.
  • the polymorphic variant comprises one or more additional polymo ⁇ hisms selected from the group consisting of thymine at PS2, guanine at PS3, adenine at PS4, thymine at PS7, thymine at PS8 and adenine at PS9.
  • a particularly preferred polymorphic variant is a naturally-occurring isoform (also referred to herein as an "isogene") of the HTRIA gene.
  • An HTRIA isogene of the invention comprises cytosine or thymine at PS 1 , cytosine or thymine at PS2, adenine or guanine at PS3, guanine or adenine at PS4, cytosine or thymine at PS5, cytosine or guanine at PS6, cytosine or thymine at PS7, guanine or thymine at PS8 and guanine or adenine at PS9 .
  • the invention also provides a collection of HTRIA isogenes, referred to herein as an HTRIA genome anthology.
  • An HTRIA isogene may be defined by the combination and order of these polymo ⁇ hisms in the isogene, which is referred to herein as an HTRIA haplotype.
  • the invention also provides data on the number of different HTRIA haplotypes found in the above four population groups. This haplotype data is useful in methods for deriving an HTRIA haplotype from an individual's genotype for the HTRIA gene and for determining an association between an HTRIA haplotype and a particular trait.
  • the invention provides a polynucleotide comprising a polymo ⁇ hic variant of a reference sequence for an HTRIA cDNA or a fragment thereof.
  • the reference sequence comprises SEQ ID NO:4 (Fig. 4) and the polymo ⁇ hic cDNA comprises at least one polymo ⁇ hism selected from the group consisting of thymine at a position corresponding to nucleotide 423 and guanine at a position corresponding to nucleotide 464.
  • the polymo ⁇ hic variant comprises one or more polymo ⁇ hisms selected from the group consisting of thymine at a position corresponding to nucleotide 47, guanine at a position corresponding to nucleotide 82, adenine at a position corresponding to nucleotide 294, thymine at a position corresponding to nucleotide 552, thymine at a position corresponding to nucleotide 659 and adenine at a position corresponding to nucleotide 818.
  • Polynucleotides complementary to these HTRIA genomic and cDNA variants are also provided by the invention.
  • the invention provides a recombinant expression vector comprising one of the polymo ⁇ hic genomic variants operably linked to expression regulatory elements as well as a recombinant host cell transformed or transfected with the expression vector.
  • the recombinant vector and host cell may be used to express HTRIA for protein structure analysis and drug binding studies.
  • the invention provides a polypeptide comprising a polymo ⁇ hic variant of a reference amino acid sequence for the HTRIA protein.
  • the reference amino acid sequence comprises SEQ ID NO:5 (Fig. 5) and the polymo ⁇ hic variant comprises the variant amino acid glycine at a position corresponding to amino acid position 155.
  • the polymo ⁇ hic variant also comprises at least one variant amino acid selected from the group consisting of leucine at a position corresponding to amino acid position 16, valine at a position corresponding to amino acid position 28, leucine at a position corresponding to amino acid position 220 and aspartic acid at a position corresponding to amino acid position 273.
  • a polymo ⁇ hic variant of HTRIA is useful in studying the effect of the variation on the biological activity of HTRIA as well as studying the binding affinity of candidate drugs targeting HTRIA for the treatment of neuropsychiatric diseases and Tourette's syndrome.
  • the present invention also provides antibodies that recognize and bind to the above polymo ⁇ hic HTRIA protein variant. Such antibodies can be utilized in a variety of diagnostic and prognostic formats and therapeutic methods.
  • the invention provides methods, compositions, and kits for haplotyping and/or genotyping the HTRIA gene in an individual.
  • the methods involve identifying the nucleotide or nucleotide pair present at one or more polymo ⁇ hic sites selected from PS1, PS5 and PS6 in one or both copies of the HTRIA gene from the individual.
  • the compositions contain oligonucleotide probes and primers designed to specifically hybridize to one or more target regions containing, or that are adjacent to, a polymo ⁇ hic site.
  • the methods and compositions for establishing the genotype or haplotype of an individual at the novel polymo ⁇ hic sites described herein are useful for studying the effect of the polymo ⁇ hisms in the etiology of diseases affected by the expression and function of the HTRIA protein, studying the efficacy of drugs targeting HTRIA, predicting individual susceptibility to diseases affected by the expression and function of the HTRIA protein and predicting individual responsiveness to drugs targeting HTRIA.
  • the invention provides a method for identifying an association between a genotype or haplotype and a trait.
  • the trait is susceptibility to a disease, severity of a disease, the staging of a disease or response to a drug.
  • the present invention also provides transgenic animals comprising one of the HTRIA genomic polymo ⁇ hic variants described herein and methods for producing such animals.
  • the transgenic animals are useful for studying expression of the HTRIA isogenes in vivo, for in vivo screening and testing of drugs targeted against HTRIA protein, and for testing the efficacy of therapeutic agents and compounds for neuropsychiatric diseases and Tourette's syndrome in a biological system.
  • the present invention also provides a computer system for storing and displaying polymo ⁇ hism data determined for the HTRIA gene.
  • the computer system comprises a computer processing unit; a display; and a database containing the polymo ⁇ hism data.
  • the polymo ⁇ hism data includes the polymo ⁇ hisms, the genotypes and the haplotypes identified for the HTRIA gene in a reference population.
  • the computer system is capable of producing a display showing HTRIA haplotypes organized according to their evolutionary relationships.
  • Figure 1 illustrates a partial reference sequence for the HTRIA gene (Genbank Version Number Z 11168.1 ; contiguous lines; SEQ ID NO: 1 ), with the start and stop positions of each region of coding sequence indicated with a bracket ([ or ]) and the numerical position below the sequence and the polymo ⁇ hic sites and polymo ⁇ hisms identified by Applicants in a reference population indicated by the variant nucleotide positioned below the polymo ⁇ hic site in the seqence.
  • Figure 2 illustrates a partial reference sequence for the HTRIA gene (Genbank Version Number M83181.1; contiguous lines; SEQ ID NO:2), with the start and stop positions of each region of coding sequence indicated with a bracket ([ or ]) and the numerical position below the sequence and the polymo ⁇ hic sites and polymo ⁇ hisms identified by Applicants in a reference population indicated by the variant nucleotide positioned below the polymo ⁇ hic site in the seqence.
  • Figure 3 a reference sequence for the HTRIA gene (contiguous lines; SEQ ID NO:3), which comprises nucleotides 1-784 of GenBank Accession No. Zl 1168.1 followed by nucleotides 1-1938 of GenBank Accession No. M83181.1, with the start and stop positions of each region of coding sequence indicated with a bracket ([ or ]) and the numerical position below the sequence and the polymo ⁇ hic sites and polymo ⁇ hisms identified by Applicants in a reference population indicated by the variant nucleotide positioned below the polymo ⁇ hic site in the seqence.
  • Figure 4 illustrates a reference sequence for the HTRIA coding sequence (contiguous lines; SEQ ID NO:4) with the polymo ⁇ hic sites and polymo ⁇ hisms identified by Applicants in a reference population indicated by the variant nucleotide positioned below the polymo ⁇ hic site in the seqence.
  • Figure 5 illustrates a reference sequence for the HTRIA protein (contiguous lines; SEQ ID NO:5) with the variant amino acids caused by the polymo ⁇ hisms of Figure 4 positioned below the polymo ⁇ hic site in the sequence.
  • the present invention is based on the discovery of novel variants of the HTRIA gene.
  • the inventors herein discovered 3 novel polymo ⁇ hic sites by characterizing the HTRIA gene found in genomic DNAs isolated from an Index Repository that contains immortalized cell lines from one chimpanzee and 93 human individuals.
  • the human individuals included a reference population of 79 unrelated individuals self-identified as belonging to one of four major population groups: Caucasian (22 individuals), African descent (20 individuals) Asian (20 individuals) Hispanic/Latino (17 individuals). To the extent possible, the members of this reference population were organized into population subgroups by the self-identified ethnogeographic origin of their four grandparents as shown in Table 1 below.
  • the Index Repository contains three unrelated indigenous American Indians (one from each of North, Central and South America), one three-generation Caucasian family (from the CEPH Utah cohort) and one two-generation African- American family.
  • the inventors herein also determined the haplotypes found on each chromosome for most human members of this repository.
  • the HTRIA genotypes and haplotypes found in the repository include those shown in Tables 4 and 5, respectively.
  • the polymo ⁇ hism and haplotype data disclosed herein are useful for studying population diversity, anthropological lineage, the significance of diversity and lineage at the phenotypic level, paternity testing, forensic applications, and for identifying associations between the HTRIA genetic variation and a trait such as level of drug response or susceptibility to disease.
  • Allele - A particular form of a genetic locus, distinguished from other forms by its particular nucleotide sequence.
  • Candidate Gene - A gene which is hypothesized to be responsible for a disease, condition, or the response to a treatment, or to be correlated with one of these.
  • Gene - A segment of DNA that contains all the information for the regulated biosynthesis of an
  • RNA product including promoters, exons, introns, and other untranslated regions that control expression.
  • Genotype An unphased 5 ' to 3 ' sequence of nucleotide pair(s) found at one or more polymo ⁇ hic sites in a locus on a pair of homologous chromosomes in an individual.
  • genotype includes a full-genotype and or a sub-genotype as described below.
  • Full-genotype The unphased 5 ' to 3 ' sequence of nucleotide pairs found at all known polymo ⁇ hic sites in a locus on a pair of homologous chromosomes in a single individual.
  • Sub-genotype The unphased 5 ' to 3 ' sequence of nucleotides seen at a subset of the known polymo ⁇ hic sites in a locus on a pair of homologous chromosomes in a single individual.
  • Genotyping A process for determining a genotype of an individual.
  • Haplotype A 5 ' to 3 ' sequence of nucleotides found at one or more polymo ⁇ hic sites in a locus on a single chromosome from a single individual.
  • haplotype includes a full-haplotype and/or a sub-haplotype as described below.
  • Full-haplotype The 5 ' to 3 ' sequence of nucleotides found at all known polymo ⁇ hic sites in a locus on a single chromosome from a single individual.
  • Sub-haplotype The 5 ' to 3 ' sequence of nucleotides seen at a subset of the known polymo ⁇ hic sites in a locus on a single chromosome from a single individual.
  • Haplotype pair The two haplotypes found for a locus in a single individual.
  • Haplotyping A process for determining one or more haplotypes in an individual and includes use of family pedigrees, molecular techniques and/or statistical inference.
  • Haplotype data Information concerning one or more of the following for a specific gene: a listing of the haplotype pairs in each individual in a population; a listing of the different haplotypes in a population; frequency of each haplotype in that or other populations, and any known associations between one or more haplotypes and a trait.
  • Isoform - A particular form of a gene, mRNA, cDNA or the protein encoded thereby, distinguished from other forms by its particular sequence and/or structure.
  • Isogene - One of the isoforms of a gene found in a population.
  • An isogene contains all of the polymo ⁇ hisms present in the particular isoform of the gene.
  • Isolated - As applied to a biological molecule such as RNA, DNA, oligonucleotide, or protein, isolated means the molecule is substantially free of other biological molecules such as nucleic acids, proteins, lipids, carbohydrates, or other material such as cellular debris and growth media. Generally, the term “isolated” is not intended to refer to a complete absence of such material or to absence of water, buffers, or salts, unless they are present in amounts that substantially interfere with the methods of the present invention.
  • Locus - A location on a chromosome or DNA molecule corresponding to a gene or a physical or phenotypic feature.
  • Naturally-occurring - A term used to designate that the object it is applied to, e.g., naturally- occurring polynucleotide or polypeptide, can be isolated from a source in nature and which has not been intentionally modified by man.
  • Nucleotide pair The nucleotides found at a polymo ⁇ hic site on the two copies of a chromosome from an individual.
  • Phased As applied to a sequence of nucleotide pairs for two or more polymo ⁇ hic sites in a locus, phased means the combination of nucleotides present at those polymo ⁇ hic sites on a single copy of the locus is known.
  • Polymorphism The sequence variation observed in an individual at a polymo ⁇ hic site.
  • Polymo ⁇ hisms include nucleotide substitutions, insertions, deletions and microsatellites and may, but need not, result in detectable differences in gene expression or protein function.
  • Polymorphism data Information concerning one or more of the following for a specific gene: location of polymo ⁇ hic sites; sequence variation at those sites; frequency of polymo ⁇ hisms in one or more populations; the different genotypes and/or haplotypes determined for the gene; frequency of one or more of these genotypes and/or haplotypes in one or more populations; any known association(s) between a trait and a genotype or a haplotype for the gene.
  • Polymorphism Database A collection of polymo ⁇ hism data arranged in a systematic or methodical way and capable of being individually accessed by electronic or other means.
  • Polynucleotide - A nucleic acid molecule comprised of single-stranded RNA or DNA or comprised of complementary, double-stranded DNA.
  • Reference Population A group of individuals sharing a common ethnogeographic origin.
  • Reference Population A group of subjects or individuals who are predicted to be representative of the genetic variation found in the general population.
  • the reference population represents the genetic variation in the population at a certainty level of at least 85%, preferably at least 90%, more preferably at least 95% and even more preferably at least 99%.
  • SNP Single Nucleotide Polymorphism
  • Subject A human individual whose genotypes or haplotypes or response to treatment or disease state are to be determined.
  • Treatment A stimulus administered internally or externally to a subject.
  • Unphased As applied to a sequence of nucleotide pairs for two or more polymo ⁇ hic sites in a locus, unphased means the combination of nucleotides present at those polymo ⁇ hic sites on a single copy of the locus is not known.
  • the inventors herein have discovered 3 novel polymo ⁇ hic sites in the HTRIA gene.
  • the polymo ⁇ hic sites identified by the inventors are referred to as PS 1 -9 to designate the order in which they are located in the gene (see Table 3 below), with the novel polymo ⁇ hic sites referred to as PSl, PS5 and PS6.
  • the invention provides an isolated polynucleotide comprising a polymo ⁇ hic variant of the HTRIA gene or a fragment of the gene which contains at least one of the novel polymo ⁇ hic sites PSl, PS5 and PS6 described herein.
  • nucleotide sequence of a variant HTRIA gene is identical to the reference genomic sequence for those portions of the gene examined, as described in the Examples below, except that it comprises a different nucleotide at one or more of the novel polymo ⁇ hic sites PS 1 , PS5 and PS6, and may also comprise one or more additional polymo ⁇ hisms selected from the group consisting of thymine at PS2, guanine at PS3, adenine at PS4, thymine at PS7, thymine at PS8 and adenine at PS9.
  • nucleotide sequence of a variant fragment of the HTRIA gene is identical to the corresponding portion of the reference sequence except for having a different nucleotide at one or more of the novel polymo ⁇ hic sites described herein.
  • the invention specifically does not include polynucleotides comprising a nucleotide sequence identical to the reference sequence (or other reported HTRIA sequences) or to portions of the reference sequence (or other reported HTRIA sequences), except for genotyping oligonucleotides as described below.
  • polymo ⁇ hism in a variant gene or fragment is identified by aligning its sequence against SEQ ID NO:3.
  • the polymo ⁇ hism is selected from the group consisting of thymine at PSl, thymine at PS5 and guanine at PS6.
  • the polymo ⁇ hic variant comprises a naturally-occurring isogene of the HTRIA gene which is defined by any one of haplotypes 1-10 shown in Table 5 below.
  • Polymo ⁇ hic variants of the invention may be prepared by isolating a clone containing the HTRIA gene from a human genomic library.
  • the clone may be sequenced to determine the identity of the nucleotides at the polymo ⁇ hic sites described herein. Any particular variant claimed herein could be prepared from this clone by performing in vitro mutagenesis using procedures well-known in the art.
  • HTRIA isogenes may be isolated using any method that allows separation of the two "copies" of the HTRIA gene present in an individual, which, as readily understood by the skilled artisan, may be the same allele or different alleles.
  • Separation methods include targeted in vivo cloning (TIVC) in yeast as described in WO 98/01573, U.S. Patent No. 5,866,404, and copending U.S. application Serial No. 08/987,966.
  • Another method which is described in copending U.S. Application Serial No. 08/987,966, uses an allele specific oligonucleotide in combination with primer extension and exonuclease degradation to generate hemizygous DNA targets.
  • Yet other methods are single molecule dilution (SMD) as described in Ruano et al., Proc. Natl. Acad. Sci.
  • the invention also provides HTRIA genome anthologies, which are collections of HTRIA isogenes found in a given population.
  • the population may be any group of at least two individuals, including but not limited to a reference population, a population group, a family population, a clinical population, and a same sex population.
  • An HTRIA genome anthology may comprise individual HTRIA isogenes stored in separate containers such as microtest tubes, separate wells of a microtitre plate and the like. Alternatively, two or more groups of the HTRIA isogenes in the anthology may be stored in separate containers.
  • a preferred HTRIA genome anthology of the invention comprises a set of isogenes defined by the haplotypes shown in Table 5 below.
  • An isolated polynucleotide containing a polymo ⁇ hic variant nucleotide sequence of the invention may be operably linked to one or more expression regulatory elements in a recombinant expression vector capable of being propagated and expressing the encoded HTRIA protein in a prokaryotic or a eukaryotic host cell.
  • expression regulatory elements which may be used include, but are not limited to, the lac system, operator and promoter regions of phage lambda, yeast promoters, and promoters derived from vaccinia virus, adenovirus, retroviruses, or SV40.
  • regulatory elements include, but are not limited to, appropriate leader sequences, termination codons, polyadenylation signals, and other sequences required for the appropriate transcription and subsequent translation of the nucleic acid sequence in a given host cell.
  • the expression vector contains any additional elements necessary for its transfer to and subsequent replication in the host cell. Examples of such elements include, but are not limited to, origins of replication and selectable markers.
  • Such expression vectors are commercially available or are readily constructed using methods known to those in the art (e.g., F. Ausubel et al., 1987, in "Current Protocols in Molecular Biology", John Wiley and Sons, New York, New York).
  • Host cells which may be used to express the variant HTRIA sequences of the invention include, but are not limited to, eukaryotic and mammalian cells, such as animal, plant, insect and yeast cells, and prokaryotic cells, such as E. coli, or algal cells as known in the art.
  • the recombinant expression vector may be introduced into the host cell using any method known to those in the art including, but not limited to, microinjection, electroporation, particle bombardment, transduction, and transfection using DEAE-dextran, lipofection, or calcium phosphate (see e.g., Sambrook et al. (1989) in "Molecular Cloning. A Laboratory Manual", Cold Spring Harbor Press, Plainview, New York).
  • eukaryotic expression vectors that function in eukaryotic cells, and preferably mammalian cells, are used.
  • Non-limiting examples of such vectors include vaccinia virus vectors, adenovirus vectors, he ⁇ es virus vectors, and baculovirus transfer vectors.
  • Preferred eukaryotic cell lines include COS cells, CHO cells, HeLa cells, NIH/3T3 cells, and embryonic stem cells (Thomson, J. A. et al., 1998 Science 282:1145-1147).
  • Particularly preferred host cells are mammalian cells.
  • polymo ⁇ hic variants of the HTRIA gene will produce HTRIA mRNAs varying from each other at any polymo ⁇ hic site retained in the spliced and processed mRNA molecules.
  • These mRNAs can be used for the preparation of an HTRIA cDNA comprising a nucleotide sequence which is a polymo ⁇ hic variant of the HTRIA reference coding sequence shown in Figure 4.
  • the invention also provides HTRIA mRNAs and corresponding cDNAs which comprise a nucleotide sequence that is identical to SEQ ID NO:4 (Fig.
  • RNA sequence except for having one or both polymo ⁇ hisms selected from the group consisting of thymine at a position corresponding to nucleotide 423 and guanine at a position corresponding to nucleotide 464, and may also comprise one or more polymo ⁇ hisms selected from the group consisting of thymine at a position corresponding to nucleotide 47, guanine at a position corresponding to nucleotide 82, adenine at a position corresponding to nucleotide 294, thymine at a position corresponding to nucleotide 552, thymine at a position corresponding to nucleotide 659 and adenine at a position corresponding to nucleotide 818.
  • Fragments of these variant mRNAs and cDNAs are included in the scope of the invention, provided they contain the novel polymo ⁇ hisms described herein.
  • the invention specifically excludes polynucleotides identical to previously identified and characterized HTRIA cDNAs and fragments thereof.
  • Polynucleotides comprising a variant RNA or DNA sequence may be isolated from a biological sample using well-known molecular biological procedures or may be chemically synthesized.
  • Genomic and cDNA fragments of the invention comprise at least one novel polymo ⁇ hic site identified herein and have a length of at least 10 nucleotides and may range up to the full length of the gene.
  • a fragment according to the present invention is between 100 and 3000 nucleotides in length, and more preferably between 200 and 2000 nucleotides in length, and most preferably between 500 and 1000 nucleotides in length.
  • nucleic acid molecules containing the HTRIA gene may be complementary double stranded molecules and thus reference to a particular site on the sense strand refers as well to the corresponding site on the complementary antisense strand.
  • reference may be made to the same polymo ⁇ hic site on either strand and an oligonucleotide may be designed to hybridize specifically to either strand at a target region containing the polymo ⁇ hic site.
  • the invention also includes single-stranded polynucleotides which are complementary to the sense strand of the HTRIA genomic variants described herein.
  • Polynucleotides comprising a polymo ⁇ hic gene variant or fragment may be useful for therapeutic pu ⁇ oses.
  • an expression vector encoding the isoform may be administered to the patient.
  • the patient may be one who lacks the HTRIA isogene encoding that isoform or may already have at least one copy of that isogene.
  • HTRIA HTRIA isogene
  • Expression of an HTRIA isogene may be turned off by transforming a targeted organ, tissue or cell population with an expression vector that expresses high levels of untranslatable mRNA for the isogene.
  • oligonucleotides directed against the regulatory regions (e.g., promoter, introns, enhancers, 3' untranslated region) of the isogene may block transcription. Oligonucleotides targeting the transcription initiation site, e.g., between positions -10 and +10 from the start site are preferred.
  • inhibition of transcription can be achieved using oligonucleotides that base-pair with region(s) of the isogene DNA to form triplex DNA (see e.g., Gee et al. in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing Co., Mt. Kisco, N.Y., 1994).
  • Antisense oligonucleotides may also be designed to block translation of HTRIA mRNA transcribed from a particular isogene. It is also contemplated that ribozymes may be designed that can catalyze the specific cleavage of HTRIA mRNA transcribed from a particular isogene.
  • the oligonucleotides may be delivered to a target cell or tissue by expression from a vector introduced into the cell or tissue in vivo or ex vivo.
  • the oligonucleotides may be formulated as a pharmaceutical composition for administration to the patient.
  • Oligoribonucleotides and/or oligodeoxynucleotides intended for use as antisense oligonucleotides may be modified to increase stability and half-life.
  • Possible modifications include, but are not limited to phosphorothioate or 2' O- methyl linkages, and the inclusion of nontraditional bases such as inosine and queosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytosine, guanine, thymine, and uracil which are not as easily recognized by endogenous nucleases.
  • the invention also provides an isolated polypeptide comprising a polymo ⁇ hic variant of the reference HTRIA amino acid sequence shown in 5.
  • the location of a variant amino acid in an HTRIA polypeptide or fragment of the invention is identified by aligning its sequence against Fig. 5.
  • An HTRIA protein variant of the invention comprises an amino acid sequence identical to SEQ ID NO:5 except for having glycine at a position corresponding to amino acid position 155, and may also comprise one or more variant amino acids selected from the group consisting of leucine at a position corresponding to amino acid position 16, valine at a position corresponding to amino acid position 28, leucine at a position corresponding to amino acid position 220 and aspartic acid at a position corresponding to amino acid position 273.
  • HTRIA protein variants included within the invention comprise all amino acid sequences based on SEQ ID NO: 5 and having the combination of amino acid variations described in Table 2 below.
  • an HTRIA protein variant of the invention is encoded by an isogene defined by one of the observed haplotypes shown in Table 5.
  • the invention also includes HTRIA peptide variants, which are any fragments of an HTRIA protein variant that contains one or more of the amino acid variations shown in Table 2.
  • An HTRIA peptide variant is at least 6 amino acids in length and is preferably any number between 6 and 30 amino acids long, more preferably between 10 and 25, and most preferably between 15 and 20 amino acids long.
  • Such HTRIA peptide variants may be useful as antigens to generate antibodies specific for one of the above HTRIA isoforms.
  • the HTRIA peptide variants may be useful in drug screening assays.
  • An HTRIA variant protein or peptide of the invention may be prepared by chemical synthesis or by expressing one of the variant HTRIA genomic and cDNA sequences as described above.
  • the HTRIA protein variant may be isolated from a biological sample of an individual having an HTRIA isogene which encodes the variant protein.
  • a biological sample contains two different HTRIA isoforms (i.e., the individual has different HTRIA isogenes)
  • a particular HTRIA isoform of the invention can be isolated by immunoaffinity chromatography using an antibody which specifically binds to that particular HTRIA isoform but does not bind to the other HTRIA isoform.
  • the expressed or isolated HTRIA protein may be detected by methods known in the art, including Coomassie blue staining, silver staining, and Western blot analysis using antibodies specific for the isoform of the HTRIA protein as discussed further below.
  • HTRIA variant proteins can be purified by standard protein purification procedures known in the art, including differential precipitation, molecular sieve chromatography, ion-exchange chromatography, isoelectric focusing, gel electrophoresis, affinity and immunoaffinity chromatography and the like. (Ausubel et. al., 1987, In Current Protocols in Molecular Biology John Wiley and Sons, New York, New York). In the case of immunoaffinity chromatography, antibodies specific for a particular polymo ⁇ hic variant may be used.
  • a polymo ⁇ hic variant HTRIA gene of the invention may also be fused in frame with a heterologous sequence to encode a chimeric HTRIA protein.
  • the non-HTRl A portion of the chimeric protein may be recognized by a commercially available antibody.
  • the chimeric protein may also be engineered to contain a cleavage site located between the HTRIA and non-HTRl A portions so that the HTRIA protein may be cleaved and purified away from the non-HTRl A portion.
  • An additional embodiment of the invention relates to using a novel HTRIA protein isoform in any of a variety of drug screening assays.
  • Such screening assays may be performed to identify agents that bind specifically to all known HTRIA protein isoforms or to only a subset of one or more of these isoforms.
  • the agents may be from chemical compound libraries, peptide libraries and the like.
  • the HTRIA protein or peptide variant may be free in solution or affixed to a solid support.
  • high throughput screening of compounds for binding to an HTRIA variant may be accomplished using the method described in PCT application WO84/03565, in which large numbers of test compounds are synthesized on a solid substrate, such as plastic pins or some other surface, contacted with the HTRIA protein(s) of interest and then washed. Bound HTRIA protein(s) are then detected using methods well-known in the art.
  • a novel HTRIA protein isoform may be used in assays to measure the binding affinities of one or more candidate drugs targeting the HTRIA protein.
  • the invention provides antibodies specific for and immunoreactive with one or more of the novel HTRIA variant proteins described herein.
  • the antibodies may be either monoclonal or polyclonal in origin.
  • the HTRIA protein or peptide variant used to generate the antibodies may be from natural or recombinant sources or produced by chemical synthesis using synthesis techniques known in the art. If the HTRIA protein variant is of insufficient size to be antigenic, it may be conjugated, complexed, or otherwise covalently linked to a carrier molecule to enhance the antigenicity of the peptide.
  • carrier molecules include, but are not limited to, albumins (e.g., human, bovine, fish, ovine), and keyhole limpet hemocyanin (Basic and Clinical Immunology, 1991, Eds. D.P. Stites, and A.I. Terr, Appleton and Lange, Norwalk Connecticut, San Mateo, California).
  • an antibody specifically immunoreactive with one of the novel HTRIA protein isoforms described herein is administered to an individual to neutralize activity of the HTRIA isoform expressed by that individual.
  • the antibody may be formulated as a pharmaceutical composition which includes a pharmaceutically acceptable carrier.
  • Antibodies specific for and immunoreactive with one of the novel HTRIA protein isoform described herein may be used to immunoprecipitate the HTRIA protein variant from solution as well as react with HTRIA protein isoforms on Western or immunoblots of polyacrylamide gels on membrane supports or substrates.
  • the antibodies will detect HTRIA protein isoforms in paraffin or frozen tissue sections, or in cells which have been fixed or unfixed and prepared on slides, coverslips, or the like, for use in immunocytochemical, immunohistochemical, and immunofluorescence techniques.
  • an antibody specifically immunoreactive with one of the novel HTRIA protein variants described herein is used in immunoassays to detect this variant in biological samples.
  • an antibody of the present invention is contacted with a biological sample and the formation of a complex between the HTRIA protein variant and the antibody is detected.
  • suitable immunoassays include radioimmunoassay, Western blot assay, immunofluorescent assay, enzyme linked immunoassay (ELISA), chemiluminescent assay, immunohistochemical assay, immunocytochemical assay, and the like (see, e.g., Principles and Practice of Immunoassay, 1991, Eds. Christopher P. Price and David J.
  • Neoman Stockton Press, New York, New York; Current Protocols in Molecular Biology, 1987, Eds. Ausubel et al., John Wiley and Sons, New York, New York).
  • Standard techniques known in the art for ELISA are described in Methods in Immunodiagnosis, 2nd Ed., Eds. Rose and Bigazzi, John Wiley and Sons, New York 1980; and Campbell et al., 1984, Methods in Immunology, W.A. Benjamin, Inc.).
  • Such assays may be direct, indirect, competitive, or noncompetitive as described in the art (see, e.g., Principles and Practice of Immunoassay, 1991, Eds. Christopher P. Price and David J.
  • Proteins may be isolated from test specimens and biological samples by conventional methods, as described in Current Protocols in Molecular Biology, supra.
  • Exemplary antibody molecules for use in the detection and therapy methods of the present invention are intact immunoglobulin molecules, substantially intact immunoglobulin molecules, or those portions of immunoglobulin molecules that contain the antigen binding site.
  • Polyclonal or monoclonal antibodies may be produced by methods conventionally known in the art (e.g., Kohler and Milstein, 1975, Nature, 256:495-497; Campbell Monoclonal Antibody Technology, the Production and Characterization of Rodent and Human Hybridomas, 1985, In: Laboratory Techniques in Biochemistry and Molecular Biology, Eds. Burdon et al., Volume 13, Elsevier Science Publishers, Amsterdam).
  • the antibodies or antigen binding fragments thereof may also be produced by genetic engineering. The technology for expression of both heavy and light chain genes in E.
  • coli is the subject of PCT patent applications, publication number WO 901443, WO 901443 and WO 9014424 and in Huse et al., 1989, Science, 246: 1275-1281.
  • the antibodies may also be humanized (e.g., Queen, C. et al. 1989 Proc. Natl. Acad. Sci. 86; 10029). Effect(s) of the polymo ⁇ hisms identified herein on expression of HTRIA may be investigated by preparing recombinant cells and/or organisms, preferably recombinant animals, containing a polymo ⁇ hic variant of the HTRIA gene.
  • expression includes but is not limited to one or more of the following: transcription of the gene into precursor mRNA; splicing and other processing of the precursor mRNA to produce mature mRNA; mRNA stability; translation of the mature mRNA into HTRIA protein (including codon usage and tRNA availability); and glycosylation and/or other modifications of the translation product, if required for proper expression and function.
  • the desired HTRIA isogene may be introduced into the cell in a vector such that the isogene remains extrachromosomal. In such a situation, the gene will be expressed by the cell from the extrachromosomal location.
  • the HTRIA isogene is introduced into a cell in such a way that it recombines with the endogenous HTRIA gene present in the cell. Such recombination requires the occurrence of a double recombination event, thereby resulting in the desired HTRIA gene polymo ⁇ hism.
  • Vectors for the introduction of genes both for recombination and for extrachromosomal maintenance are known in the art, and any suitable vector or vector construct may be used in the invention.
  • HTRIA HTRIA co-precipitation
  • viral transduction for introducing DNA into cells are known in the art; therefore, the choice of method may lie with the competence and preference of the skilled practitioner.
  • examples of cells into which the HTRIA isogene may be introduced include, but are not limited to, continuous culture cells, such as COS, NIH/3T3, and primary or culture cells of the relevant tissue type, i.e., they express the HTRIA isogene.
  • Such recombinant cells can be used to compare the biological activities of the different protein variants.
  • Recombinant organisms i.e., transgenic animals, expressing a variant HTRIA gene are prepared using standard procedures known in the art.
  • a construct comprising the variant gene is introduced into a nonhuman animal or an ancestor of the animal at an embryonic stage, i.e., the one-cell stage, or generally not later than about the eight-cell stage.
  • Transgenic animals carrying the constructs of the invention can be made by several methods known to those having skill in the art.
  • One method involves transfecting into the embryo a retrovirus constructed to contain one or more insulator elements, a gene or genes of interest, and other components known to those skilled in the art to provide a complete shuttle vector harboring the insulated gene(s) as a transgene, see e.g., U.S. Patent No. 5,610,053.
  • Another method involves directly injecting a transgene into the embryo.
  • a third method involves the use of embryonic stem cells. Examples of animals into which the HTRIA isogenes may be introduced include, but are not limited to, mice, rats, other rodents, and nonhuman primates (see "The Introduction of Foreign Genes into Mice" and the cited references therein, In: Recombinant DNA, Eds. J.D. Watson, M.
  • Transgenic animals stably expressing a human HTRIA isogene and producing human HTRIA protein can be used as biological models for studying diseases related to abnormal HTRIA expression and/or activity, and for screening and assaying various candidate drugs, compounds, and treatment regimens to reduce the symptoms or effects of these diseases.
  • compositions for treating disorders affected by expression or function of a novel HTRIA isogene described herein may comprise any of the following active ingredients: a polynucleotide comprising one of these novel HTRIA isogenes; an antisense oligonucleotide directed against one of the novel HTRIA isogenes, a polynucleotide encoding such an antisense oligonucleotide, or another compound which inhibits expression of a novel HTRIA isogene described herein.
  • the composition contains the active ingredient in a therapeutically effective amount.
  • composition also comprises a pharmaceutically acceptable carrier, examples of which include, but are not limited to, saline, buffered saline, dextrose, and water.
  • a pharmaceutically acceptable carrier examples of which include, but are not limited to, saline, buffered saline, dextrose, and water.
  • Those skilled in the art may employ a formulation most suitable for the active ingredient, whether it is a polynucleotide, oligonucleotide, protein, peptide or small molecule antagonist.
  • the pharmaceutical composition may be administered alone or in combination with at least one other agent, such as a stabilizing compound.
  • Administration of the pharmaceutical composition may be by any number of routes including, but not limited to oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, intradermal, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, PA).
  • the therapeutically effective dose of active ingredient and or the appropriate route of administration is well within the capability of those skilled in the art.
  • the dose can be estimated initially either in cell culture assays or in animal models.
  • the animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.
  • the exact dosage will be determined by the practitioner, in light of factors relating to the patient requiring treatment, including but not limited to severity of the disease state, general health, age, weight and gender of the patient, diet, time and frequency of administration, other drugs being taken by the patient, and tolerance/response to the treatment.
  • Information on the identity of genotypes and haplotypes for the HTRIA gene of any particular individual as well as the frequency of such genotypes and haplotypes in any particular population of individuals is expected to be useful for a variety of basic research and clinical applications.
  • the invention also provides compositions and methods for detecting the novel HTRIA polymo ⁇ hisms identified herein.
  • compositions comprise at least one HTRIA genotyping oligonucleotide.
  • an HTRIA genotyping oligonucleotide is a probe or primer capable of hybridizing to a target region that is located close to, or that contains, one of the novel polymo ⁇ hic sites described herein.
  • the term "oligonucleotide” refers to a polynucleotide molecule having less than about 100 nucleotides.
  • a preferred oligonucleotide of the invention is 10 to 35 nucleotides long. More preferably, the oligonucleotide is between 15 and 30, and most preferably, between 20 and 25 nucleotides in length.
  • oligonucleotide may be comprised of any phosphorylation state of ribonucleotides, deoxyribonucleotides, and acyclic nucleotide derivatives, and other functionally equivalent derivatives.
  • oligonucleotides may have a phosphate-free backbone, which may be comprised of linkages such as carboxymethyl, acetamidate, carbamate, polyamide (peptide nucleic acid (PNA)) and the like (Varma, R. in Molecular Biology and Biotechnology, A Comprehensive Desk Reference, Ed. R. Meyers, VCH Publishers, Inc. (1995), pages 617-620).
  • Oligonucleotides of the invention may be prepared by chemical synthesis using any suitable methodology known in the art, or may be derived from a biological sample, for example, by restriction digestion.
  • the oligonucleotides may be labeled, according to any technique known in the art, including use of radiolabels, fluorescent labels, enzymatic labels, proteins, haptens, antibodies, sequence tags and the like.
  • Genotyping oligonucleotides of the invention must be capable of specifically hybridizing to a target region of an HTRIA polynucleotide, i.e., an HTRIA isogene.
  • specific hybridization means the oligonucleotide forms an anti-parallel double-stranded structure with the target region under certain hybridizing conditions, while failing to form such a structure when incubated with a non-target region or a non-HTRl A polynucleotide under the same hybridizing conditions.
  • the oligonucleotide specifically hybridizes to the target region under conventional high stringency conditions.
  • the skilled artisan can readily design and test oligonucleotide probes and primers suitable for detecting polymo ⁇ hisms in the HTRIA gene using the polymo ⁇ hism information provided herein in conjunction with the known sequence information for the HTRIA gene and routine techniques.
  • a nucleic acid molecule such as an oligonucleotide or polynucleotide is said to be a "perfect” or “complete” complement of another nucleic acid molecule if every nucleotide of one of the molecules is complementary to the nucleotide at the corresponding position of the other molecule.
  • a nucleic acid molecule is "substantially complementary” to another molecule if it hybridizes to that molecule with sufficient stability to remain in a duplex form under conventional low-stringency conditions. Conventional hybridization conditions are described, for example, by Sambrook J. et al., in Molecular Cloning, A Laboratory Manual, 2 nd Edition, Cold Spring Harbor Press, Cold Spring Harbor, NY (1989) and by Haymes, B.D.
  • an oligonucleotide primer may have a non-complementary fragment at its 5 ' end, with the remainder of the primer being complementary to the target region.
  • non-complementary nucleotides may be interspersed into the oligonucleotide probe or primer as long as the resulting probe or primer is still capable of specifically hybridizing to the target region.
  • Preferred genotyping oligonucleotides of the invention are allele-specific oligonucleotides.
  • ASO allele-specific oligonucleotide
  • allele-specificity will depend upon a variety of readily optimized stringency conditions, including salt and formamide concentrations, as well as temperatures for both the hybridization and washing steps.
  • Allele-specific oligonucleotide probes which usually provide good discrimination between different alleles are those in which a central position of the oligonucleotide probe aligns with the polymo ⁇ hic site in the target region (e.g., approximately the 7 th or 8 th position in a 15 mer, the 8 th or 9 th position in a 16mer, the 10 th or 11 th position in a 20 mer).
  • a preferred ASO probe for detecting HTRIA gene polymo ⁇ hisms comprises a nucleotide sequence, listed 5' to 3', selected from the group consisting of: GGAGCGCCTGAAAGC ( SEQ ID NO : 6 ) and its complement ,
  • GGAGCGCTTGAAAGC SEQ ID NO : 7
  • CGGACCCCATCGACT SEQ ID NO : 8
  • CGGACCCTATCGACT SEQ ID NO : 9
  • GCCGCTGCGCTCATC SEQ ID NO : 10
  • GCCGCTGGGCTCATC SEQ ID NO : 11
  • An allele-specific oligonucleotide primer of the invention has a 3 ' terminal nucleotide, or preferably a 3 ' penultimate nucleotide, that is complementary to only one nucleotide of a particular SNP, thereby acting as a primer for polymerase-mediated extension only if the allele containing that nucleotide is present. Allele-specific oligonucleotide primers hybridizing to either the coding or noncoding strand are contemplated by the invention.
  • a preferred ASO primer for detecting HTRIA gene polymo ⁇ hisms comprises a nucleotide sequence, listed 5 ' to 3 ', selected from the group consisting of: GCCCAGGGAGCGCCT (SEQ ID NO: 12) GGAGCAGCTTTCAGG (SEQ ID NO: 13) GCCCAGGGAGCGCTT (SEQ ID NO: 14) GGAGCAGCTTTCAAG (SEQ ID NO: 15) CCATCACGGACCCCA (SEQ ID NO: 16) TCACGTAGTCGATGG (SEQ ID NO: 17)
  • genotyping oligonucleotides of the invention hybridize to a target region located one to several nucleotides downstream of one of the novel polymo ⁇ hic sites identified herein. Such oligonucleotides are useful in polymerase-mediated primer extension methods for detecting one of the novel polymo ⁇ hisms described herein and therefore such genotyping oligonucleotides are referred to herein as "primer-extension oligonucleotides".
  • the 3 '-terminus of a primer- extension oligonucleotide is a deoxynucleotide complementary to the nucleotide located immediately adjacent to the polymo ⁇ hic site.
  • a particularly preferred oligonucleotide primer for detecting HTRIA gene polymo ⁇ hisms by primer extension terminates in a nucleotide sequence, listed 5' to 3', selected from the group consisting of:
  • CAGGGAGCGC (SEQ ID NO: 24 ) ; GCAGCTTTCA (SEQ ID NO: 25); TCACGGACCC (SEQ ID NO: 26) ; CGTAGTCGAT (SEQ ID NO:27); CGCGCCGCTG (SEQ ID NO: 28); and CGAGATGAGC (SEQ ID NO: 29).
  • a composition contains two or more differently labeled genotyping oligonucleotides for simultaneously probing the identity of nucleotides at two or more polymo ⁇ hic sites. It is also contemplated that primer compositions may contain two or more sets of allele-specific primer pairs to allow simultaneous targeting and amplification of two or more regions containing a polymo ⁇ hic site.
  • HTRIA genotyping oligonucleotides of the invention may also be immobilized on or synthesized on a solid surface such as a microchip, bead, or glass slide (see, e.g., WO 98/20020 and WO 98/20019). Such immobilized genotyping oligonucleotides may be used in a variety of polymo ⁇ hism detection assays, including but not limited to probe hybridization and polymerase extension assays. Immobilized HTRIA genotyping oligonucleotides of the invention may comprise an ordered array of oligonucleotides designed to rapidly screen a DNA sample for polymo ⁇ hisms in multiple genes at the same time.
  • the invention provides a kit comprising at least two genotyping oligonucleotides packaged in separate containers.
  • the kit may also contain other components such as hybridization buffer (where the oligonucleotides are to be used as a probe) packaged in a separate container.
  • the kit may contain, packaged in separate containers, a polymerase and a reaction buffer optimized for primer extension mediated by the polymerase, such as PCR.
  • the above described oligonucleotide compositions and kits are useful in methods for genotyping and/or haplotyping the HTRIA gene in an individual.
  • HTRIA genotype and “HTRIA haplotype” mean the genotype or haplotype contains the nucleotide pair or nucleotide, respectively, that is present at one or more of the novel polymo ⁇ hic sites described herein and may optionally also include the nucleotide pair or nucleotide present at one or more additional polymo ⁇ hic sites in the HTRIA gene.
  • the additional polymo ⁇ hic sites may be currently known polymo ⁇ hic sites or sites that are subsequently discovered.
  • One embodiment of the genotyping method involves isolating from the individual a nucleic acid mixture comprising the two copies of the HTRIA gene, or a fragment thereof, that are present in the individual, and determining the identity of the nucleotide pair at one or more of the polymo ⁇ hic sites selected from PSl, PS5 and PS6 in the two copies to assign an HTRIA genotype to the individual.
  • the two "copies" of a gene in an individual may be the same allele or may be different alleles.
  • the identity of the nucleotide pair atone or more of the polymo ⁇ hic sites selected from the group consisting of PS3, PS4 and PS8 is also determined.
  • the genotyping method comprises determining the identity of the nucleotide pair at each of PS1-9.
  • the nucleic acid mixture is isolated from a biological sample taken from the individual, such as a blood sample or tissue sample.
  • tissue samples include whole blood, semen saliva, tears, urine, fecal material, sweat, buccal, skin and hair.
  • the nucleic acid mixture may be comprised of genomic DNA, mRNA, or cDNA and, in the latter two cases, the biological sample must be obtained from an organ in which the HTRIA gene is expressed.
  • mRNA or cDNA preparations would not be used to detect polymo ⁇ hisms located in introns or in 5 ' and 3' nontranscribed regions. If an HTRIA gene fragment is isolated, it must contain the polymo ⁇ hic site(s) to be genotyped.
  • One embodiment of the haplotyping method comprises isolating from the individual a nucleic acid molecule containing only one of the two copies of the HTRIA gene, or a fragment thereof, that is present in the individual and determining in that copy the identity of the nucleotide at one or more of the polymo ⁇ hic sites PSl, PS5 and PS6 in that copy to assign an HTRIA haplotype to the individual.
  • the nucleic acid may be isolated using any method capable of separating the two copies of the HTRIA gene or fragment such as one of the methods described above for preparing HTRIA isogenes, with targeted in vivo cloning being the preferred approach.
  • the haplotyping method also comprises identifying the nucleotide at one or more of the polymo ⁇ hic sites PS2, PS3, PS4 , PS7, PS8 andn PS9. In a particularly preferred embodiment, the nucleotide at each of PS 1-9 is identified.
  • an HTRIA haplotype pair is determined for an individual by identifying the phased sequence of nucleotides at one or more of the polymo ⁇ hic sites selected from PSl, PS5 and PS6 in each copy of the HTRIA gene that is present in the individual.
  • the haplotyping method comprises identifying the phased sequence of nucleotides at each of PS1-9 in each copy of the HTRIA gene.
  • the identifying step is preferably performed with each copy of the gene being placed in separate containers.
  • the two copies are labeled with different tags, or are otherwise separately distinguishable or identifiable, it could be possible in some cases to perform the method in the same container.
  • first and second copies of the gene are labeled with different first and second fluorescent dyes, respectively, and an allele-specific oligonucleotide labeled with yet a third different fluorescent dye is used to assay the polymo ⁇ hic site(s), then detecting a combination of the first and third dyes would identify the polymo ⁇ hism in the first gene copy while detecting a combination of the second and third dyes would identify the polymo ⁇ hism in the second gene copy.
  • the identity of a nucleotide (or nucleotide pair) at a polymo ⁇ hic site(s) may be determined by amplifying a target region(s) containing the polymo ⁇ hic site(s) directly from one or both copies of the HTRIA gene, or fragment thereof, and the sequence of the amplified region(s) determined by conventional methods. It will be readily appreciated by the skilled artisan that only one nucleotide will be detected at a polymo ⁇ hic site in individuals who are homozygous at that site, while two different nucleotides will be detected if the individual is heterozygous for that site.
  • the polymo ⁇ hism may be identified directly, known as positive-type identification, or by inference, referred to as negative-type identification.
  • a site may be positively determined to be either guanine or cytosine for an individual homozygous at that site, or both guanine and cytosine, if the individual is heterozygous at that site.
  • the site may be negatively determined to be not guanine (and thus cytosine/cytosine) or not cytosine (and thus guanine/guanine).
  • the identity of the allele(s) present at any of the novel polymo ⁇ hic sites described herein may be indirectly determined by genotyping a polymo ⁇ hic site not disclosed herein that is in linkage disequilibrium with the polymo ⁇ hic site that is of interest. Two sites are said to be in linkage disequilibrium if the presence of a particular variant at one site enhances the predictability of another variant at the second site (Stevens, JC 1999, Mol. Diag. 4: 309-17). Polymo ⁇ hic sites in linkage disequilibrium with the presently disclosed polymo ⁇ hic sites may be located in regions of the gene or in other genomic regions not examined herein.
  • Genotyping of a polymo ⁇ hic site in linkage disequilibrium with the novel polymo ⁇ hic sites described herein may be performed by, but is not limited to, any of the above-mentioned methods for detecting the identity of the allele at a polymo ⁇ hic site.
  • the target region(s) may be amplified using any oligonucleotide-directed amplification method, including but not limited to polymerase chain reaction (PCR) (U.S. Patent No. 4,965,188), ligase chain reaction (LCR) (Barany et al., Proc. Natl. Acad. Sci.
  • Oligonucleotide ligation assay OLA
  • Oligonucleotides useful as primers or probes in such methods should specifically hybridize to a region of the nucleic acid that contains or is adjacent to the polymo ⁇ hic site.
  • the oligonucleotides are between 10 and 35 nucleotides in length and preferably, between 15 and 30 nucleotides in length. Most preferably, the oligonucleotides are 20 to 25 nucleotides long. The exact length of the oligonucleotide will depend on many factors that are routinely considered and practiced by the skilled artisan.
  • nucleic acid amplification procedures may be used to amplify the target region including transcription-based amplification systems (U.S. Patent No. 5,130,238; EP 329,822; U.S. Patent No. 5,169,766, WO89/06700) and isothermal methods (Walker et al., Proc. Natl. Acad. Sci. USA 89:392- 396, 1992).
  • a polymo ⁇ hism in the target region may also be assayed before or after amplification using one of several hybridization-based methods known in the art.
  • allele-specific oligonucleotides are utilized in performing such methods.
  • the allele-specific oligonucleotides may be used as differently labeled probe pairs, with one member of the pair showing a perfect match to one variant of a target sequence and the other member showing a perfect match to a different variant.
  • more than one polymo ⁇ hic site may be detected at once using a set of allele-specific oligonucleotides or oligonucleotide pairs.
  • the members of the set have melting temperatures within 5°C, and more preferably within 2°C, of each other when hybridizing to each of the polymo ⁇ hic sites being detected.
  • Hybridization of an allele-specific oligonucleotide to a target polynucleotide may be performed with both entities in solution, or such hybridization may be performed when either the oligonucleotide or the target polynucleotide is covalently or noncovalently affixed to a solid support. Attachment may be mediated, for example, by antibody-antigen interactions, poly-L-Lys, streptavidin or avidin-biotin, salt bridges, hydrophobic interactions, chemical linkages, UV cross-linking baking, etc. Allele-specific oligonucleotides may be synthesized directly on the solid support or attached to the solid support subsequent to synthesis.
  • Solid-supports suitable for use in detection methods of the invention include substrates made of silicon, glass, plastic, paper and the like, which may be formed, for example, into wells (as in 96-well plates), slides, sheets, membranes, fibers, chips, dishes, and beads.
  • the solid support may be treated, coated or derivatized to facilitate the immobilization of the allele-specific oligonucleotide or target nucleic acid.
  • the genotype or haplotype for the HTRIA gene of an individual may also be determined by hybridization of a nucleic sample containing one or both copies of the gene to nucleic acid arrays and subarrays such as described in WO 95/11995.
  • the arrays would contain a battery of allele-specific oligonucleotides representing each of the polymo ⁇ hic sites to be included in the genotype or haplotype.
  • the identity of polymo ⁇ hisms may also be determined using a mismatch detection technique, including but not limited to the RNase protection method using riboprobes (Winter et al., Proc. Natl. Acad. Sci.
  • variant alleles can be identified by single strand conformation polymo ⁇ hism
  • SSCP serum-derived DNA sequence
  • DGGE denaturing gradient gel electrophoresis
  • a polymerase-mediated primer extension method may also be used to identify the polymo ⁇ hism(s).
  • multiple polymo ⁇ hic sites may be investigated by simultaneously amplifying multiple regions of the nucleic acid using sets of allele-specific primers as described in Wallace et al. (WO89/10414).
  • an individual's HTRIA haplotype pair is predicted from its HTRIA genotype using information on haplotype pairs known to exist in a reference population.
  • the haplotyping prediction method comprises identifying an HTRIA genotype for the individual at two or more polymo ⁇ hic sites selected from PS 1 , PS5 and PS6, enumerating all possible haplotype pairs which are consistent with the genotype, accessing data containing HTRIA haplotype pairs identified in a reference population, and assigning a haplotype pair to the individual that is consistent with the data.
  • the reference haplotype pairs include the HTRIA haplotype pairs shown in Table 4.
  • the reference population should be composed of randomly-selected individuals representing the major ethnogeographic groups of the world.
  • a preferred reference population allows the detection of any haplotype whose frequency is at least 10% with about 99% certainty and comprises about 20 unrelated individuals from each of the four population groups named above.
  • a particularly preferred reference population includes a 3-generation family representing one or more of the four population groups to serve as controls for checking quality of haplotyping procedures.
  • the haplotype frequency data for each ethnogeographic group is examined to determine whether it is consistent with Hardy- Weinberg equilibrium. Hardy- Weinberg equilibrium (D.L.
  • haplotyping the individual using a direct haplotyping method such as, for example, CLASPER System TM technology (U.S. Patent No. 5,866,404), SMD, or allele-specific long-range PCR (Michalotos-Beloin et al., Nucleic Acids Res. 24:4841-4843, 1996).
  • CLASPER System TM technology U.S. Patent No. 5,866,404
  • SMD SMD
  • allele-specific long-range PCR Moichalotos-Beloin et al., Nucleic Acids Res. 24:4841-4843, 1996.
  • the assigning step involves performing the following analysis. First, each of the possible haplotype pairs is compared to the haplotype pairs in the reference population. Generally, only one of the haplotype pairs in the reference population matches a possible haplotype pair and that pair is assigned to the individual. Occasionally, only one haplotype represented in the reference haplotype pairs is consistent with a possible haplotype pair for an individual, and in such cases the individual is assigned a haplotype pair containing this known haplotype and a new haplotype derived by subtracting the known haplotype from the possible haplotype pair.
  • the individual is preferably haplotyped using a direct molecular haplotyping method such as, for example, CLASPER System TM technology (U.S. Patent No. 5,866,404), SMD, or allele-specific long-range PCR (Michalotos-Beloin et al., Nucleic Acids Res. 24:4841-4843, 1996).
  • a direct molecular haplotyping method such as, for example, CLASPER System TM technology (U.S. Patent No. 5,866,404), SMD, or allele-specific long-range PCR (Michalotos-Beloin et al., Nucleic Acids Res. 24:4841-4843, 1996).
  • the invention also provides a method for determining the frequency of an HTRIA genotype or HTRIA haplotype in a population.
  • the method comprises determining the genotype or the haplotype pair for the HTRIA gene that is present in each member of the population, wherein the genotype or haplotype comprises the nucleotide pair or nucleotide detected at one or more of the polymo ⁇ hic sites PSl, PS5 and PS6 in the HTRIA gene; and calculating the frequency any particular genotype or haplotype is found in the population.
  • the population may be a reference population, a family population, a same sex population, a population group, a trait population (e.g., a group of individuals exhibiting a trait of interest such as a medical condition or response to a therapeutic treatment).
  • a trait population e.g., a group of individuals exhibiting a trait of interest such as a medical condition or response to a therapeutic treatment.
  • frequency data for HTRIA genotypes and/or haplotypes found in a reference population are used in a method for identifying an association between a trait and an HTRIA genotype or an HTRIA haplotype.
  • the trait may be any detectable phenotype, including but not limited to susceptibility to a disease or response to a treatment.
  • the method involves obtaining data on the frequency of the genotype(s) or haplotype(s) of interest in a reference population as well as in a population exhibiting the trait.
  • Frequency data for one or both of the reference and trait populations may be obtained by genotyping or haplotyping each individual in the populations using one of the methods described above.
  • the haplotypes for the trait population may be determined directly or, alternatively, by the predictive genotype to haplotype approach described above.
  • the frequency data for the reference and/or trait populations is obtained by accessing previously determined frequency data, which may be in written or electronic form.
  • the frequency data may be present in a database that is accessible by a computer.
  • the frequencies of the genotype(s) or haplotype(s) of interest in the reference and trait populations are compared.
  • the frequencies of all genotypes and/or haplotypes observed in the populations are compared. If a particular genotype or haplotype for the HTRIA gene is more frequent in the trait population than in the reference population at a statistically significant amount, then the trait is predicted to be associated with that HTRIA genotype or haplotype.
  • the HTRIA genotype or haplotype being compared in the trait and reference populations is selected from the full-genotypes and full- haplotypes shown in Tables 4 and 5, respectively, or from sub-genotypes and sub-haplotypes derived from these genotypes and haplotypes.
  • the trait of interest is a clinical response exhibited by a patient to some therapeutic treatment, for example, response to a drug targeting HTRIA or response to a therapeutic treatment for a medical condition.
  • medical condition includes but is not limited to any condition or disease manifested as one or more physical and/or psychological symptoms for which treatment is desirable, and includes previously and newly identified diseases and other disorders.
  • clinical response means any or all of the following: a quantitative measure of the response, no response, and adverse response (i.e., side effects).
  • clinical population a population of individuals who received the treatment
  • This clinical data may be obtained by analyzing the results of a clinical trial that has already been run and/or the clinical data may be obtained by designing and carrying out one or more new clinical trials.
  • clinical trial means any research study designed to collect clinical data on responses to a particular treatment, and includes but is not limited to phase I, phase II and phase III clinical trials. Standard methods are used to define the patient population and to enroll subjects.
  • the individuals included in the clinical population have been graded for the existence of the medical condition of interest. This is important in cases where the symptom(s) being presented by the patients can be caused by more than one underlying condition, and where treatment of the underlying conditions are not the same. An example of this would be where patients experience breathing difficulties that are due to either asthma or respiratory infections. If both sets were treated with an asthma medication, there would be a spurious group of apparent non-responders that did not actually have asthma. These people would affect the ability to detect any correlation between haplotype and treatment outcome.
  • This grading of potential patients could employ a standard physical exam or one or more lab tests. Alternatively, grading of patients could use haplotyping for situations where there is a strong correlation between haplotype pair and disease susceptibility or severity.
  • the therapeutic treatment of interest is administered to each individual in the trial population and each individual's response to the treatment is measured using one or more predetermined criteria. It is contemplated that in many cases, the trial population will exhibit a range of responses and that the investigator will choose the number of responder groups (e.g., low, medium, high) made up by the various responses.
  • the HTRIA gene for each individual in the trial population is genotyped and/or haplotyped, which may be done before or after administering the treatment. After both the clinical and polymo ⁇ hism data have been obtained, correlations between individual response and HTRIA genotype or haplotype content are created. Correlations may be produced in several ways.
  • individuals are grouped by their HTRIA genotype or haplotype (or haplotype pair) (also referred to as a polymo ⁇ hism group), and then the averages and standard deviations of clinical responses exhibited by the members of each polymo ⁇ hism group are calculated.
  • a second method for finding correlations between HTRIA haplotype content and clinical responses uses predictive models based on error-minimizing optimization algorithms.
  • One of many possible optimization algorithms is a genetic algorithm (R. Judson, "Genetic Algorithms and Their Uses in Chemistry” in Reviews in Computational Chemistry, Vol. 10, pp. 1-73, K. B. Lipkowitz and D. B.
  • Correlations may also be analyzed using analysis of variation (ANOVA) techniques to determine how much of the variation in the clinical data is explained by different subsets of the polymo ⁇ hic sites in the PTGS2 gene.
  • ANOVA analysis of variation
  • a mathematical model may be readily constructed by the skilled artisan that predicts clinical response as a function of HTRIA genotype or haplotype content.
  • the model is validated in one or more follow-up clinical trials designed to test the model.
  • the identification of an association between a clinical response and a genotype or haplotype (or haplotype pair) for the HTRIA gene may be the basis for designing a diagnostic method to determine those individuals who will or will not respond to the treatment, or alternatively, will respond at a lower level and thus may require more treatment, i.e., a greater dose of a drug.
  • the diagnostic method may take one of several forms: for example, a direct DNA test (i.e., genotyping or haplotyping one or more of the polymo ⁇ hic sites in the HTRIA gene), a serological test, or a physical exam measurement.
  • a direct DNA test i.e., genotyping or haplotyping one or more of the polymo ⁇ hic sites in the HTRIA gene
  • serological test i.e., a serological test
  • a physical exam measurement i.e., a physical exam measurement.
  • this diagnostic method uses the predictive haplotyping method described above.
  • any or all analytical and mathematical operations involved in practicing the methods of the present invention may be implemented by a computer.
  • the computer may execute a program that generates views (or screens) displayed on a display device and with which the user can interact to view and analyze large amounts of information relating to the HTRIA gene and its genomic variation, including chromosome location, gene structure, and gene family, gene expression data, polymo ⁇ hism data, genetic sequence data, and clinical data population data (e.g., data on ethnogeographic origin, clinical responses, genotypes, and haplotypes for one or more populations).
  • the HTRIA polymo ⁇ hism data described herein may be stored as part of a relational database (e.g., an instance of an Oracle database or a set of ASCII flat files).
  • polymo ⁇ hism data may be stored on the computer's hard drive or may, for example, be stored on a CD ROM or on one or more other storage devices accessible by the computer.
  • the data may be stored on one or more databases in communication with the computer via a network.
  • Example 1 This example illustrates examination of various regions of the HTRIA gene for polymo ⁇ hic sites.
  • the following target regions of the HTRIA gene were amplified using the PCR primer pairs listed below, with the sequences presented in the 5 ' to 3 ' direction and nucleotide positions shown for each region corresponding to the indicated GenBank Accession No.
  • Amplification profile 94°C - 2 min. 1 cycle
  • PCR products were purified by Solid Phase Reversible Immobilization using the protocol developed by the Whitehead Genome Center. A detailed protocol can be found at http://www.genome.wi.mit.edu/sequencing protocols/pure/SPRI_pcr.html.
  • Example 2 This example illustrates analysis of the HTRIA polymo ⁇ hisms identified in the Index Repository for human genotypes and haplotypes.
  • the different genotypes containing these polymo ⁇ hisms that were observed in the reference population are shown in Table 4 below, with the haplotype pair indicating the combination of haplotypes determined for the individual using the haplotype derivation protocol described below.
  • Table 4 homozygous positions are indicated by one nucleotide and heterozygous positions are indicated by two nucleotides Missing nucleotides in any given genotype in Table 4 can typically be inferred based on linkage disequilibrium and/or Mendelian inheritance. Table 4. Genotypes and 1Haplotype Pairs Observeid for HTRIA Gene
  • haplotype pairs shown in Table 4 were estimated from the unphased genotypes using an extension of Clark's algorithm (Clark, A.G. (1990) Mol Bio Evol 7, 111-122), as described in U.S. Provisional Patent Application filed April 19, 2000 and entitled "A Method and System for Determining Haplotypes from a Collection of Polymo ⁇ hisms".
  • haplotypes are assigned directly from individuals who are homozygous at all sites or heterozygous at no more than one of the variable sites. This list of haplotypes is then used to deconvolute the unphased genotypes in the remaining (multiply heterozygous) individuals.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Cette invention concerne des polynucléotides un ou plus de 3 nouveaux polymorphismes nucléotidiques uniques dans le gène récepteur 1A de la 5-hydroxytryptamine humaine (HTR1A). L'invention porte également sur des compositions et des méthodes de détection d'un ou de plusieurs de ces polymorphismes ainsi que divers génotypes et haplotypes pour le gène HTR1A qui existent dans la population.
EP00962018A 1999-08-06 2000-08-01 Isogenes cibles pour medicament: polymorphismes dans le gene recepteur 1a de la 5-hydroxytryptamine Withdrawn EP1208112A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14771199P 1999-08-06 1999-08-06
US147711P 1999-08-06
PCT/US2000/040519 WO2001010884A1 (fr) 1999-08-06 2000-08-01 Isogenes cibles pour medicament: polymorphismes dans le gene recepteur 1a de la 5-hydroxytryptamine

Publications (1)

Publication Number Publication Date
EP1208112A1 true EP1208112A1 (fr) 2002-05-29

Family

ID=22522622

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00962018A Withdrawn EP1208112A1 (fr) 1999-08-06 2000-08-01 Isogenes cibles pour medicament: polymorphismes dans le gene recepteur 1a de la 5-hydroxytryptamine

Country Status (4)

Country Link
EP (1) EP1208112A1 (fr)
JP (1) JP2003506070A (fr)
AU (1) AU7388700A (fr)
WO (1) WO2001010884A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040254363A1 (en) * 2001-07-16 2004-12-16 Andrew Bergen Genes and snps associated with eating disorders
EP1694666A4 (fr) * 2003-12-19 2008-09-17 Philadelphia Health & Educatio Nouveaux recepteurs 5-ht1a episses, procedes, necessaires et utilisations correspondants
EP1951910A4 (fr) * 2005-11-30 2010-02-03 Univ North Carolina Identification de variants polymorphiques genetiques associes aux troubles somatosensoriels et procedes d'utilisation de ces derniers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0110884A1 *

Also Published As

Publication number Publication date
JP2003506070A (ja) 2003-02-18
AU7388700A (en) 2001-03-05
WO2001010884A1 (fr) 2001-02-15

Similar Documents

Publication Publication Date Title
AU2000278349A1 (en) Drug target isogenes: polymorphisms in the interleukin 13 gene
WO2002006294A2 (fr) Haplotypes du gene mmp13
WO2001005832A1 (fr) Isogenes cibles de medicament: polymorphismes dans le gene d2 du recepteur de dopamine
WO2001090123A2 (fr) Haplotypes du gene agtrl1
WO2002012497A2 (fr) Haplotypes du gene nfkbib
WO2001027312A2 (fr) Isogenes cibles pour medicaments: polymorphismes dans le gene recepteur de l'acetylcholine muscarinique m1
EP1208112A1 (fr) Isogenes cibles pour medicament: polymorphismes dans le gene recepteur 1a de la 5-hydroxytryptamine
EP1208194A2 (fr) Isogenes cibles de medicaments : polymorphismes dans le gene de la sous-unite alpha du recepteur i de l'immunoglobuline e
WO2001029176A2 (fr) Isogenes cibles de medicaments: polymorphismes dans le gene 3 muscarinique, de recepteur cholinergique
WO2001090120A2 (fr) Haplotypes du gene evx1
WO2002018657A1 (fr) Haplotypes du gene d'or11a1
WO2001079232A2 (fr) Haplotypes du gene mpl
WO2001090127A2 (fr) Haplotypes du gene de hoxd3
WO2001079240A2 (fr) Haplotypes du gene rangap1
WO2002050098A2 (fr) Haplotypes du gene du recepteur de la prolactine (prlr)
WO2002063045A1 (fr) Isogenes cibles de medicament: polymorphismes dans le gene du recepteur 2 de l'angiotensine
WO2001027313A2 (fr) Isogenes cibles pour medicaments: polymorphisme dans le gene muscarinique 2 recepteur cholinergique
WO2001027311A2 (fr) Isogenes cibles de medicaments: les polymorphismes du gene recepteur 1d de la 5-hydroxytryptamine (serotonine)
WO2001018232A2 (fr) Isogenes cibles de medicaments: polymorphismes dans le gene de proteine bruleuse de graisses excedentaires (mitochondriale, porteuse de protons)
WO2001014588A1 (fr) Isogenes cibles de medicament: polymorphismes dans le gene de la chaine beta du recepteur e d'immunoglobuline
WO2001090128A2 (fr) Haplotypes du gene gpr3
WO2002002820A1 (fr) Haplotypes du gene appbp1
WO2002026770A2 (fr) Haplotypes du gene admr
WO2001087908A2 (fr) Haplotypes du gene ccr3
WO2001096350A2 (fr) Haplotypes du gene grm3

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020301

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040301